Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01921
European Journal of Endocrinology, Vol 152, Issue 6, 825-833
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (12)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Storr, H. L
Right arrow Articles by Savage, M. O
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Storr, H. L
Right arrow Articles by Savage, M. O

CLINICAL STUDY

Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing’s disease

Helen L Storr1, Farhad Afshar2, Matthew Matson3, Ian Sabin5, Kate M Davies5, Jane Evanson5, P Nicholas Plowman4, G Michael Besser1, John P Monson1, Ashley B Grossman1 and Martin O Savage1

1 Departments of Endocrinology, 2 Neurosurgery, 3 Radiology and 4 Radiotherapy, St Bartholomew’s Hospital, London, UK and 5 The Royal London School of Medicine and Dentistry, London EC1A 7BE, UK

(Correspondence should be addressed to M O Savage, Paediatric Endocrinology Section, Department of Endocrinology, St Bartholomew’s Hospital, London EC1A 7BE, UK; Email: m.o.savage{at}qmul.ac.uk)

Objective: Early diagnosis and effective treatment of paediatric Cushing’s disease (CD) is necessary to minimise associated morbidity. Accepted first-line treatment is selective transsphenoidal microadenomectomy (TSS), which can be technically difficult, and cure rates vary considerably between centres. In our paediatric CD patient group we have assessed the possible factors which may influence cure by TSS.

Subjects and methods: From 1983–2004, 27 paediatric patients (16 males, 11 females; mean age±S.D., 13.1±3.2 yr; range, 6.4–17.8 yr) with CD were managed in our centre and underwent TSS. Sixteen patients (59%), seven males and nine females (mean age±S.D., 14.2±2.5 yr; range, 8.2–17.8 yr), were cured (post-operative serum cortisol < 50 nM). Eleven patients, nine males and two females (mean age±S.D., 11.5±3.6 yr; range, 6.4–17.8 yr) had post-operative cortisol levels above 50 nM (2–20 days), with mean serum cortisol levels at 09:00 h of 537 nM (range 269–900 nM) indicating a lack of cure. These 11 patients received external beam pituitary radiotherapy (RT). One patient with a pituitary macroadenoma had a post-operative cortisol level of < 50 nM but 0.8 yr later showed an elevated cortisol and residual disease.

Results: The patients cured by TSS alone were significantly older than those not cured (P = 0.038; Student’s t test). All patients had CT/MRI pituitary imaging: 14 were reported to have microadenomas and one macroadenoma, while 12 were reported as normal. Bilateral simultaneous inferior petrosal sinus sampling (BSIPSS) with i.v. corticotropin-releasing hormone (CRH) administration was introduced as a pre-operative investigation in 1986 and was performed in 21 patients (78%), on BSIPSS, 16 (76%) had evidence suggesting pituitary adrenocorticotropic hormone (ACTH) secretion (central to peripheral (IPS:P) ACTH ratio after CRH of ≥ 3.0) and 16 (76%) showed lateralisation of ACTH secretion (IPSG of ≥ 1.4). There was concordance between the BSIPSS finding and the position of the microadenoma at surgery in 17/21 (81%) patients. Of the 16 patients showing lateralisation of ACTH secretion, 12 (75%) were cured by TSS. Of the four without lateralisation of ACTH, suggesting a midline lesion, 3 (75%) were cured by TSS. Post-operative pituitary hormone deficiencies in the patients cured by TSS were: pan-hypopituitarism 1/16, isolated growth hormone deficiency (GHD) (peak GH on glucagon/ITT < 1–17.9 mU/l) 9/16 and diabetes insipidus 3/16.

Conclusion: Over a 21-year period selective adenomectomy by TSS cured 59% of all paediatric CD patients, with higher age favouring cure. Introduction of BSIPSS resulted in the demonstration of a high rate of lateralisation of ACTH secretion consistent with the surgical identification of the adenoma, and therefore appears likely to have contributed to the higher surgical cure rate.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
B. M. K. Biller, A. B. Grossman, P. M. Stewart, S. Melmed, X. Bertagna, J. Bertherat, M. Buchfelder, A. Colao, A. R. Hermus, L. J. Hofland, et al.
Treatment of Adrenocorticotropin-Dependent Cushing's Syndrome: A Consensus Statement
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2454 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
L F Chan, H L Storr, P N Plowman, L A Perry, G M Besser, A B Grossman, and M O Savage
Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy
Eur. J. Endocrinol., April 1, 2007; 156(4): 477 - 482.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
F. Pecori Giraldi, M. Andrioli, L. De Marinis, A. Bianchi, A. Giampietro, M. De Martin, E. Sacco, M. Scacchi, A. Pontecorvi, and F. Cavagnini
Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease
Eur. J. Endocrinol., February 1, 2007; 156(2): 233 - 239.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
C J Peters, H L Storr, A B Grossman, and M O Savage
The role of corticotrophin-releasing hormone in the diagnosis of Cushing's syndrome
Eur. J. Endocrinol., November 1, 2006; 155(suppl_1): S93 - S98.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.